ACOG

Alpha Cognition Inc.

NasdaqAdd to watchlist

$8.83

−$0.02−0.23%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$8.83

−$0.92−9.44%over 1M

Session

Day range14% of range

$8.77$9.21

Fundamentals

Visualize fundamentals and more

Market cap: 192.27M
P/E ratio: -

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 201
dropped: 201
re-drafted: 40

Out of 600 passages in this year’s Item 1A.

New this year

ZUNVEYL oral tablet formulation may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.

401 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Litigation
Reimbursement
Patent expiry
Taiwan
Currency moves
Product recalls
China

And 16 more.

FDA approval
34 Risks Related to Our Business Development ● Our business is heavily dependent on commercial success of of ZUNVEYL oral tablet formulation, our only FDA approved product, and the development and commercialization of any future product candidates that we may …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Aug 13 Quarterly report Company filing 10-Q
Jul 22 Opaleye Management Inc. bought 150,237 shares Insider trading Form 4 about $1.2M
Jun 23 Leadership change Company filing 8-K

19 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Alpha Cognition Inc. investor relations

What ACOG has filed with the SEC. This is not Alpha Cognition Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Where else ACOG appears

ACOG is among the largest companies matching:

gross margin above 70% and still lossmaking

Ask about Alpha Cognition Inc.

The assistant answers from what ACOG has actually filed: 3 annual reports filed with the SEC and 62 Form 4 filings from the last year. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from ACOG's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Alpha Cognition Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Alpha Cognition Inc.

Be told the moment a ACOG insider trades
Put Alpha Cognition Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Alpha Cognition Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Alpha Cognition Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Aug 13 Quarterly report Company filing 10-Q
Jul 22 Opaleye Management Inc. bought 150,237 shares Insider trading Form 4 about $1.2M
Jun 23 Leadership change Company filing 8-K

19 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Litigation
Reimbursement
Patent expiry
Taiwan
Currency moves
Product recalls
China

And 16 more.

FDA approval
34 Risks Related to Our Business Development ● Our business is heavily dependent on commercial success of of ZUNVEYL oral tablet formulation, our only FDA approved product, and the development and commercialization of any future product candidates that we may …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 201
dropped: 201
re-drafted: 40

Out of 600 passages in this year’s Item 1A.

New this year

ZUNVEYL oral tablet formulation may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.

401 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add